Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly Completes Avid Acquisition, Florbetapir Gets Priority Review | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly Completes Avid Acquisition, Florbetapir Gets Priority Review

Eli Lilly and Co. has completed the acquisition of Avid Radiopharmaceuticals, Inc. for an upfront payment of $300 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Co. has completed the acquisition of Avid Radiopharmaceuticals, Inc. for an upfront payment of $300 million. Avid stockholders are also eligible for as much as $500 million in additional payments based on regulatory and commercial milestones for florbetapir, Avid’s lead program in development.

The marketing application for florbetapir has received priority review designation from the FDA. Florbetapir is an investigational molecular imaging agent for detecting the presence of amyloid plaque in the brain, a defining pathology of Alzheimer’s disease. A meeting to discuss florbetapir’s NDA will take place on January 20, 2011.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters